famosan 40mg potahovaná tableta
pro.med.cs praha a.s. array - 9064 famotidin - potahovaná tableta - 40mg - famotidin
quamatel 20mg prášek a rozpouštědlo pro injekční/infuzní roztok
gedeon richter plc., budapešť array - 9064 famotidin - prášek a rozpouštědlo pro injekční/infuzní roztok - 20mg - famotidin
adempas
bayer ag - riociguat - hypertenze, plicní - antihypertenzíva pro plicní arteriální hypertenzi - chronic thromboembolic pulmonary hypertension (cteph)adempas is indicated for the treatment of adult patients with who functional class (fc) ii to iii withinoperable cteph,persistent or recurrent cteph after surgical treatment,to improve exercise capacity. pulmonary arterial hypertension (pah)adultsadempas, as monotherapy or in combination with endothelin receptor antagonists, is indicated for the treatment of adult patients with pulmonary arterial hypertension (pah) with who functional class (fc) ii to iii to improve exercise capacity. Účinnost byla prokázána v pau populace, včetně etiologie idiopatické nebo dědičné pah nebo pah spojenou s onemocněním pojivové tkáně. paediatricsadempas is indicated for the treatment of pah in paediatric patients aged less than 18 years of age and body weight ≥ 50 kg with who functional class (fc) ii to iii in combination with endothelin receptor antagonists.
tagrisso
astrazeneca ab - osimertinib mesilate - karcinom, plicní jiná než malobuněčná - jiná cytostatika, inhibitory proteinkinázy - tagrisso as monotherapy is indicated for:- the adjuvant treatment after complete tumour resection in adult patients with stage ib-iiia non-small cell lung cancer (nsclc) whose tumours have epidermal growth factor receptor (egfr) exon 19 deletions or exon 21 (l858r) substitution mutations- the first-line treatment of adult patients nsclc with activating egfr mutations. - the treatment of adult patients with locally advanced or metastatic egfr t790m mutation-positive nsclc. tagrisso as monotherapy is indicated for:- the adjuvant treatment after complete tumour resection in adult patients with stage ib-iiia non-small cell lung cancer (nsclc) whose tumours have epidermal growth factor receptor (egfr) exon 19 deletions or exon 21 (l858r) substitution mutations. - the first-line treatment of adult patients with locally advanced or metastatic nsclc with activating egfr mutations. - the treatment of adult patients with locally advanced or metastatic egfr t790m mutation-positive nsclc.
conisor 100mg tvrdá tobolka
litcon pharma se, praha 8 array - 9219 itrakonazol - tvrdá tobolka - 100mg - itrakonazol
prokanazol 100mg tvrdá tobolka
pro.med.cs praha a.s. array - 9219 itrakonazol - tvrdá tobolka - 100mg - itrakonazol
warfarin pmcs 2mg tableta
pro.med.cs praha a.s. array - 13232 klatrÁt sodnÉ soli warfarinu - tableta - 2mg - warfarin
warfarin pmcs 5mg tableta
pro.med.cs praha a.s. array - 13232 klatrÁt sodnÉ soli warfarinu - tableta - 5mg - warfarin
sporanox 10mg/ml perorální roztok
janssen-cilag s.r.o., praha array - 9219 itrakonazol - perorální roztok - 10mg/ml - itrakonazol
vizimpro
pfizer europe ma eeig - dacomitinib monohydrát - karcinom, plicní jiná než malobuněčná - antineoplastická činidla - vizimpro, jako monoterapii je indikován k první linii léčby dospělých pacientů s lokálně pokročilého nebo metastazujícího nemalobuněčného karcinomu plic (nsclc) s receptor pro epidermální růstový faktor (egfr) aktivační mutace.